FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS
Goal: to develop the model of of type 2 diabetes mellitus outcomes validated in Russian clinical conditions and to perform pharmacoeconomic evaluation of glucose lowering therapies. Materials and methods: Existing type 2 DM models were evaluated. Risk equations for type 2 DM complications were compiled. Demographic, biochemical etc. patient parameters were used as input parameters. Glucose lowering drug’s effectiveness were incorporated into the model as its ability to modify input parameters (HbA1c, lipids, etc.). Cost-effectiveness analysis was performed. Results: The developed model allows to assess the risk of type 2 DM complications in 5 years in patient with predefined risk factors. Among comparing strategies of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY – 470 120.40 RUR, which is 51% of the willingness-to-pay threshold in Russia. With the lowest complication treatment costs inside the total direct costs, liraglutide monotherapy demonstrated the most long-term sustainable glycemic control and HbA1c goal parameters..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Фармакоэкономика - 6(2015), 2, Seite 33-41 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
A. S. Kolbin [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
Cost-effectiveness analysis |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ079492355 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ079492355 | ||
| 003 | DE-627 | ||
| 005 | 20230410103224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230307s2015 xx |||||o 00| ||rus c | ||
| 035 | |a (DE-627)DOAJ079492355 | ||
| 035 | |a (DE-599)DOAJd57e4f68286245fe971029219320ef67 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a HB71-74 | |
| 100 | 0 | |a A. S. Kolbin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Goal: to develop the model of of type 2 diabetes mellitus outcomes validated in Russian clinical conditions and to perform pharmacoeconomic evaluation of glucose lowering therapies. Materials and methods: Existing type 2 DM models were evaluated. Risk equations for type 2 DM complications were compiled. Demographic, biochemical etc. patient parameters were used as input parameters. Glucose lowering drug’s effectiveness were incorporated into the model as its ability to modify input parameters (HbA1c, lipids, etc.). Cost-effectiveness analysis was performed. Results: The developed model allows to assess the risk of type 2 DM complications in 5 years in patient with predefined risk factors. Among comparing strategies of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY – 470 120.40 RUR, which is 51% of the willingness-to-pay threshold in Russia. With the lowest complication treatment costs inside the total direct costs, liraglutide monotherapy demonstrated the most long-term sustainable glycemic control and HbA1c goal parameters. | ||
| 650 | 4 | |a type 2 diabetes mellitus | |
| 650 | 4 | |a outcome modeling | |
| 650 | 4 | |a cost-effectiveness analysis | |
| 650 | 4 | |a liraglutide | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Economics as a science | |
| 700 | 0 | |a O. K. Khmelnitskiy |e verfasserin |4 aut | |
| 700 | 0 | |a A. A. Kurylev |e verfasserin |4 aut | |
| 700 | 0 | |a Yu. E. Balykina |e verfasserin |4 aut | |
| 700 | 0 | |a M. A. Proskurin |e verfasserin |4 aut | |
| 700 | 0 | |a E. P. Kolpak |e verfasserin |4 aut | |
| 700 | 0 | |a M. V. Bure |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Фармакоэкономика |d IRBIS LLC, 2019 |g 6(2015), 2, Seite 33-41 |w (DE-627)DOAJ000119067 |x 20704933 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2015 |g number:2 |g pages:33-41 |
| 856 | 4 | 0 | |u https://doaj.org/article/d57e4f68286245fe971029219320ef67 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.pharmacoeconomics.ru/jour/article/view/23 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2070-4909 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2070-4933 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2015 |e 2 |h 33-41 | ||